Harrow Inc（HROW）资讯与事件HROWHarrow Inc

Harrow Reports Q2 Revenue of $70.66M, Exceeds Expectations

Reports Q2 revenue $70.66M, consensus $70.35M. "We spent the first half of 2026 building demand and positioning the business to achieve our 2026 and 2027 financial objectives. The second half of 2026 is about converting that demand into accelerating revenue growth and profitability," said Mark L. Baum, Chairman and Chief Executive Officer of Harrow. "Over the past six months, we expanded our commercial organization, strengthened our portfolio, improved pricing across key products, launched BYOOVIZ(R), advanced multiple clinical programs, and announced the acquisition of TYRVAYA. VEVYE delivered record quarterly revenue while improving its underlying economics, and momentum continues to build, supported by our recent coverage win that went into effect August 1. IHEEZO achieved the strongest commercial quarter in its history despite the loss of pass-through reimbursement, and TRIESENCE continued to generate exceptional demand growth - reinforcing our conviction that physician demand continues to strengthen across our portfolio."

Harrow and Samsung Bioepis Present Interim Data on SB11

Harrow and Samsung Bioepis presented interim data from a post-marketing surveillance study on SB11, a biosimilar referencing Lucentis, at the Annual Meeting of the American Society of Retina Specialists. The interim report includes data from 298 patients evaluating the real-world safety and efficacy of SB11. The study demonstrated a comparable safety profile to the reference product and showed clinically meaningful efficacy improvement in treatment-naive patients while maintaining efficacy in those switched from other anti-VEGF therapies. "We believe this post-marketing surveillance data further strengthens the clinical foundation supporting BYOOVIZ, reinforcing the confidence retina specialists can have in this biosimilar option - both in treatment-naive patients and those transitioning from other anti-VEGF therapies," said Mark Baum, CEO of Harrow.

Harrow Launches BYOOVIZ Biosimilar

Harrow announced the commercial launch of BYOOVIZ, an FDA-approved biosimilar referencing LUCENTISi and developed by Samsung Bioepis. The launch follows Harrow's exclusive U.S. commercialization agreement with Samsung Bioepis, one of the world's leading biosimilar developers and manufacturers. Through this partnership, Harrow obtained exclusive U.S. rights to commercialize BYOOVIZ and OPUVIZ, an FDA-approved biosimilar referencing EYLEAii, further strengthening the Company's position in the rapidly growing retinal biologics market.